"Keep Calm And Live In New York City -The Promise Of CBD" - Rachel Syme
Many doctors believe that Cannabidiol (CBD), a non-psychoactive chemical found in marijuana and hemp plants, has genuine medicinal value. Last month, the FDA approved a CBD-based drug for the treatment of Dravet syndrome, a childhood epilepsy disorder. Yasmin Hurd, PhD, professor of psychiatry, neurology, pharmacology and systems therapeutics at the Icahn School of Medicine at Mount Sinai and director of the Center for Addictive Disorders at the Mount Sinai Health System, uses four-hundred to eight-hundred-milligram doses to study CBD’s benefit in opioid-addiction treatment. She said that hoping for therapeutic effects from a dosage as low as what’s found in commercial products like CBD coffees, which tend to contain only around twenty-five milligrams, is “ridiculous.”
- Yasmin Hurd, PhD, Professor, Psychiatry, Neuroscience, Pharmacology, Systems Therapeutics, Icahn School of Medicine at Mount Sinai, Chair, Ward-Coleman Translational Neuroscience, Director of the Center for Addictive Disorders, Mount Sinai Health System